Stay updated with breaking news from பால்ஸ் டோநிலீ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NET study: New theranostic approach effective in reducing tumor volume and extending lifespan A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as two fractionated doses, as opposed to one. ....
E-Mail IMAGE: Representative maximum intensity projection PET/CT images of AR42J tumor-bearing female Balb/c nude mice following injection of 64Cu-CuSarTATE (3 MBq, 0.24 nmol of peptide) at 1 and 4 hours post injection.. view more Credit: Images created by associate professor Carleen Cullinane (Peter MaCallum Cancer Centre). Reston, Virginia A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as ....
Date Time New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study Reston, Virginia-A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as two fractionated doses, as opposed to one. ....